|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Assets segregated for regulatory purposes and restricted cash | ||||||||||||||||||||
| Collateralized agreements | ||||||||||||||||||||
| Financial instruments, at fair value: | ||||||||||||||||||||
| Trading assets ($1,410 and $1,248 pledged as collateral) | ||||||||||||||||||||
| Available-for-sale securities ($8 and $9 pledged as collateral) | ||||||||||||||||||||
| Derivative assets | ||||||||||||||||||||
| Other investments ($20 and $8 pledged as collateral) | ||||||||||||||||||||
| Brokerage client receivables, net | ||||||||||||||||||||
| Other receivables, net | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Nonrelated party | ||||||||||||||||||||
| Related party | ||||||||||||||||||||
| Deferred income taxes, net | ||||||||||||||||||||
| Goodwill and identifiable intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and shareholders’ equity: | ||||||||||||||||||||
| Bank deposits | ||||||||||||||||||||
| Collateralized financings | ||||||||||||||||||||
| Financial instrument liabilities, at fair value: | ||||||||||||||||||||
| Trading liabilities | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Brokerage client payables | ||||||||||||||||||||
| Accrued compensation, commissions and benefits | ||||||||||||||||||||
| Other payables | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Senior notes payable | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Common stock; $.01 par value; 650,000,000 shares authorized; 250,084,168 shares issued and 192,124,666 shares outstanding as of June 30, 2026; 250,084,168 shares issued and 198,139,594 shares outstanding as of September 30, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost; 57,959,502 and 51,944,574 common shares as of June 30, 2026 and September 30, 2025, respectively | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total equity attributable to Raymond James Financial, Inc. | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
